Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stone, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stone, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Combination therapy: its rationale and the role of ezetimibe

N. Stone*

Northwestern University School of Medicine, Illinois, U.S.A.

* Correspondence: Neil Stone, MD, Professor of Clinical Medicine, Department of Cardiology, Northwestern University School of Medicine, 211 E. Chicago Ave. STE 1050, Chicago, Illinois, U.S.A.

Abstract

Despite the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of statins, many patients, especially those at the highest risk for coronary heart disease (CHD), do not reach LDL-C goals. Although there are many reasons for this observation, one possible solution is to treat hyperlipidemic patients with a combination of two lipid-altering agents that have different mechanisms of action. Several trials have illustrated the potential utility of combining resins with statins or niacin, and niacin or fibrates with statins. However, many patients poorly tolerate resins and niacin, and fibrates combined with statins may increase the risk of myopathy. An ‘dideal’ second drug to add to statins or niacin would: (a) lower LDL-C by 15–18%; (b) not potentiate the liver or muscle toxicities associated with high dose statins; and (c) cause few side effects or drug-drug interactions that would compromise compliance. Ezetimibe is a new cholesterol absorption inhibitor that exhibits all of these characteristics. Ezetimibe inhibits the intestinal absorption of dietary and biliary cholesterol without interfering with the absorption of fat-soluble vitamins. When added to statins, ezetimibe produces significant reductions in LDL-C and triglycerides beyond reductions seen with a statin alone. Moreover, ezetimibe has a favorable safety and tolerability profile without any clinically important drug interactions. Thus, the combination of statins with ezetimibe offers a promising new approach to lowering LDL-C.

Key Words: Stalin • ezetimibe • combination therapy • niacin • fibrates

References

  1. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467[Abstract/Free Full Text]
  2. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298[Abstract]
  3. Blankenhom DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–3240[Abstract/Free Full Text]
  4. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–3012[Abstract/Free Full Text]
  5. Brown BG, Zhao X-Q, Chair A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592[Abstract/Free Full Text]
  6. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80:608–613[CrossRef][Web of Science][Medline]
  7. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002;162:1568–1576[Abstract/Free Full Text]
  8. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024–1028[Free Full Text]
  9. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107[CrossRef][Web of Science][Medline]
  10. Buchwald H, Williams SE, Matts JP, Nguyen PA, Boen JR. Overall mortality in the program on the surgical control of the hyperlipidemias. J Am Coll Surg. 2002;195:327–331[CrossRef][Web of Science][Medline]
  11. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl CoA reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933–1935[Abstract/Free Full Text]
  12. Schectman G, Hiatt J. Dose-response characteristics of cholesterol lowering drug therapies: implications for treatment. Ann Intern Med. 1996;125:990–1000[Abstract/Free Full Text]
  13. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667–673[CrossRef][Web of Science][Medline]
  14. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54:309–319[CrossRef][Web of Science][Medline]
  15. Bays H, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1209–1230[CrossRef][Web of Science][Medline]
  16. Gagne C, Gaudet D, Bruckert Efor the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–2475[Abstract/Free Full Text]
  17. Stein EA. An investigative look: selective cholesterol absorption inhibitors: embarking on a new standard of care. Am J Manag Care. 2002;8(2 Suppl):S36–S39[Web of Science][Medline]
  18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22[CrossRef][Web of Science][Medline]
  19. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313–318[Abstract/Free Full Text]
  20. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J. 2001;3(Suppl E):E11–E16

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stone, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stone, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?